Abstract
N-acetyl aspartate (NAA) is a marker of neuronal integrity and metabolism. Deficiency in neuronal plasticity and hypometabolism are implicated in the pathophysiology of Major Depressive Disorder (MDD). To test if cerebral NAA concentrations decrease progressively over the MDD course, we conducted a meta-analysis of Proton Magnetic Resonance Spectroscopy (1H-MRS) studies comparing NAA concentrations in chronic MDD (cMDD) and first episode of depression (FED) to healthy controls. We searched Scopus® and Web of Knowledge □ using search terms related to depression and NAA. Hedges’ g was used as effect size measure, together with heterogeneity analyses, test of moderators and publication bias and quality assessment. The protocol is registered in PROSPERO (CRD42020221050). Sixty-two studies were included and meta-analyzed using a random-effect model for each brain region. NAA concentrations were significantly reduced in cMDD compared to healthy controls within the frontal lobe (n=26, Hedges’ g= -0.330, 95% CI -0.598 to -0.062; p= 0.018), the occipital lobe (n = 4, Hedges’ g= -0.677, 95% CI -1.013 to -0.341; p = 0.007), the thalamus (n= 4, Hedges’ g= -0.673, 95% CI -1.108 to -0.238; p = 0.016) and the frontal (n = 6, Hedges’ g= -0.471, 95% CI -0.891 to -0.052; p= 0.034) and periventricular white matter (n= 3, Hedges’ g= -0.478, 95% CI -0.938 to -0.018; p= 0.047). We highlighted a gap of knowledge regarding NAA levels in FED. Sensitivity analyses indicated that antidepressant treatment may reverse NAA alterations in the frontal lobe. Our findings are in line with previous evidence showing alterations in the aforementioned brain areas in MDD. Future studies should assess NAA alterations in the early stages of the illness and their longitudinal progression, also considering our preliminary results on the modifying effect of antidepressant treatment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020221050
Funding Statement
This work was supported by the University of Pisa, Fondi di Ateneo 2019 to G.R. G.R. is supported by the European Union's Horizon 2020 research and innovation program under the MSC grant agreement n. 101026235.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Scopus and Web of Knowledge databases
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supplemental files and main text have been updated with additional analyses concerning field strenght as a categorical moderator, as well as with formal and other minor revisions.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020221050
